Most trials were small trials without any harms reporting. Pace was intended to cover this but they did not do it properly. They changed their definition of serious adverse events (without mentioning it) and they did not check compliance with treatment. I think there could also be issues due to the review process where events are discarded as not relevant to treatments. If the reviewers don't thing GET can harm they will not allocate it as such.It's an ethical issue because people are so pro and against GET. Proponents will design a trial so that only very serious harm is recorded (not necessarily cynically but they don't expect problems).